<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105977">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02004262</url>
  </required_header>
  <id_info>
    <org_study_id>ADU-CL-04</org_study_id>
    <nct_id>NCT02004262</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting</brief_title>
  <acronym>ECLIPSE</acronym>
  <official_title>A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aduro BioTech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aduro BioTech, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test the safety, immune response and efficacy of GVAX pancreas vaccine (with
      cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with
      previously treated metastatic pancreatic adenocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival in subjects receiving test treatments</measure>
    <time_frame>Subjects followed on study for 2 years from last subject enrolled; expected duration of follow-up = 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events in each treatment arm treatment regimen</measure>
    <time_frame>Subjects followed on study for 2 years from last subject enrolled; expected duration of follow-up = 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclophosphamide (200 mg/m^2) D0 of Weeks 1, 4
GVAX Pancreas Vaccine (5 × 10e8 cells) D 1 of Weeks 1, 4
CRS-207 (1 × 10e9 CFU) Weeks 7, 10, 13, 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS-207 Weeks 1, 4, 7, 10, 13, 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib in accordance with defined treatment schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GVAX Pancreas Vaccine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRS-207</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib</intervention_name>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically proven malignant adenocarcinoma of the pancreas; measurable
             disease is not required, mixed histology is not allowed; subjects must have
             metastatic disease

          -  2nd line, 3rd line or greater

          -  At least 18 years of age

          -  ECOG of 0 or 1

          -  Anticipated life expectancy &gt;12 weeks

          -  For women and men of childbearing potential, a medically acceptable method of highly
             effective contraception (oral hormonal contraceptive, condom plus spermicide, or
             hormone implants) must be used throughout the study period and for 28 days after
             their final vaccine administration. (A barrier method of contraception must be
             employed by all subjects [male and female], regardless of other methods.)

          -  Have adequate organ function as defined by specified laboratory values

        Exclusion Criteria:

          -  Allergy to both penicillin &amp; sulfa or suspected hypersensitivity to GM-CSF, dimethyl
             sulfoxide, fetal bovine serum, trypsin, yeast, glycerol or other component of the
             therapy options

          -  Known history or evidence of brain metastases, immunodeficiency disease or
             immunocompromised state or or history of autoimmune disease requiring systemic
             steroids or other immunosuppressive treatment

          -  Have any evidence of hepatic cirrhosis or clinical or radiographic ascites

          -  A prosthetic joint or other artificial implant or device that cannot be easily
             removed (there are some exceptions)

          -  Rapidly progressing disease

          -  Clinically significant and/or malignant pleural effusion

          -  Received prior GVAX pancreas vaccine or CRS-207

          -  Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring
             within 28 days prior to receiving study drug, or planned surgery requiring general
             anesthesia

          -  Infection with HIV or hepatitis B or C at screening

          -  Valvular heart disease that requires antibiotic prophylaxis for prevention of
             endocarditis

          -  Be pregnant or breastfeeding

          -  Unable to avoid close contact with another individual known to be at high risk of
             listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during
             the course of CRS-207 treatment until completion of antibiotic regimen

          -  Conditions, including alcohol or drug dependence, intercurrent illness, or lack of
             sufficient peripheral venous access, that would affect the patient's ability to
             comply with study visits and procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scottsdale Healthcare Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN RN AOCNS</last_name>
      <phone>480-323-1339</phone>
      <phone_ext>2</phone_ext>
      <email>joschaffer@shc.org</email>
    </contact>
    <investigator>
      <last_name>Erkut Borazanci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>California</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamie Bendrick-Peart</last_name>
      <phone>720-848-0600</phone>
      <email>JAMIE.BENDRICK-PEART@UCDENVER.EDU</email>
    </contact>
    <investigator>
      <last_name>Colin Weekes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Simpson</last_name>
      <phone>858-822-7951</phone>
      <email>besimpson@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Tony Reid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Mt Zion Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>McKinley Nickerson</last_name>
      <phone>415-514-6314</phone>
      <email>NickersonM@cc.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami/Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasmine Forrester</last_name>
      <phone>305-243-0865</phone>
      <email>J.Forrester@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Hosein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenisha Allen</last_name>
      <phone>773-834-0475</phone>
      <email>Kallen@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Hedy Kindler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Kemberling, RN</last_name>
      <phone>443-287-5013</phone>
      <email>Hkember1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Dung Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Lears</last_name>
      <phone>314-747-8085</phone>
      <email>klears@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Wang-Gillam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Oprescu</last_name>
      <phone>212-304-5588</phone>
      <email>amo2135@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Fine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Morris Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ireka Burrus</last_name>
      <phone>919-668-1861</phone>
      <email>ireka.burrus@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Morse, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue-Yun To</last_name>
      <phone>503-215-2855</phone>
      <email>yue-yun.to@providence.org</email>
    </contact>
    <investigator>
      <last_name>Todd Crocenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Cancer Pavillion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Tribble</last_name>
      <phone>412-647-8205</phone>
      <email>gtribble@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Zeh III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICC Cancer Information Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Emily Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Blackwell</last_name>
      <phone>434-982-1901</phone>
      <email>CMB2BT@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Osama Rahma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Pilling</last_name>
      <phone>206-342-6908</phone>
      <email>megan.pilling@vmmc.org</email>
    </contact>
    <investigator>
      <last_name>Vincent J Picozzi, MD, MMM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernadette Southwood</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>3422</phone_ext>
      <email>bernadette.southwood@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Malcolm Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.adurobiotech.com</url>
    <description>For additional information please see Aduro's website</description>
  </link>
  <link>
    <url>http://www.pancan.org</url>
    <description>The Pancreatic Cancer Action Network's Patient &amp; Liaison Services (PALS) program provides patients and families with information and resources at no cost. Visit www.pancan.org, call 877-272-6226 or email pals@pancan.org for information.</description>
  </link>
  <reference>
    <citation>Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13.</citation>
    <PMID>15365184</PMID>
  </reference>
  <reference>
    <citation>Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6.</citation>
    <PMID>22147941</PMID>
  </reference>
  <reference>
    <citation>Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011 Feb;253(2):328-35. doi: 10.1097/SLA.0b013e3181fd271c.</citation>
    <PMID>21217520</PMID>
  </reference>
  <reference>
    <citation>Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008 Mar 1;14(5):1455-63.</citation>
    <PMID>18316569</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>cancer vaccine</keyword>
  <keyword>Listeria monocytogenes</keyword>
  <keyword>Listeria-based vaccine</keyword>
  <keyword>GVAX</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>mesothelin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
